NM yields 88.11% · ABBV yields 3.06%● Live data
📍 NM pulled ahead of the other in Year 1
Combined, NM + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NM + ABBV for your $10,000?
Navios Maritime Holdings Inc. operates as a seaborne shipping and logistics company in North America, Australia, Europe, Asia, South America, and internationally. It focuses on the transportation and transshipment of dry bulk commodities, including iron ores, coal, and grains. The company operates in two segments, Dry Bulk Vessel Operations and Logistics Business. The Dry Bulk Vessel Operations segment engages in the transportation and handling of bulk cargoes through the ownership, operation, and trading of vessels and freight. This segment charters its vessels to trading houses, producers, and government-owned entities. The Logistics Business segment operates ports and transfer station terminals, as well as upriver transport facilities in the Hidrovia region; and handles vessels, barges, push boats, and cabotage business. This segment provides its integrated transportation, storage, and related services through its port facilities, cargo barges, and product tankers to mineral and grain commodity providers, as well as to users of refined petroleum products. As of December 31, 2021, the company's fleet consisted of 36 vessels totaling 3.9 million deadweight tons. Navios Maritime Holdings Inc. was incorporated in 1954 and is headquartered in Grand Cayman, the Cayman Islands.
Full NM Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.